Publikationen

50.

Rauch A, Seitz S, Baschant U, Schilling AF, Illing A, Stride B, Kirilov M, Mandic V, Takacz A, Schmidt-Ullrich R, Ostermay S, Schinke T, Spanbroek R, Zaiss MM, Angel PE, Lerner UH, David J, Reichardt HM, Amling M, Schütz G, Tuckermann JP. Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell metabolism. 2010; 11(6):517—531.      [DOI] 

49.

Maes C, Goossens S, Bartunkova S, Drogat B, Coenegrachts L, Stockmans I, Moermans K, Nyabi O, Haigh K, Naessens M, Haenebalcke L, Tuckermann JP, Tjwa M, Carmeliet P, Mandic V, David J, Behrens A, Nagy A, Carmeliet G, Haigh JJ. Increased skeletal VEGF enhances beta-catenin activity and results in excessively ossified bones. The EMBO journal. 2010; 29(2):424—441.      [DOI] 

48.

Maes C, Goossens S, Bartunkova S, Drogat B, Coenegrachts L, Stockmans I, Moermans K, Nyabi O, Haigh K, Naessens M, Haenebalcke L, Tuckermann JP, Tjwa M, Carmeliet P, Mandic V, David J, Behrens A, Nagy A, Carmeliet G, Haigh JJ. Increased skeletal VEGF enhances beta-catenin activity and results in excessively ossified bones. The EMBO journal. 2010; 29(2):424—441.      [DOI] 

47.

Maes C, Goossens S, Bartunkova S, Drogat B, Coenegrachts L, Stockmans I, Moermans K, Nyabi O, Haigh K, Naessens M, Haenebalcke L, Tuckermann JP, Tjwa M, Carmeliet P, Mandic V, David J, Behrens A, Nagy A, Carmeliet G, Haigh JJ. Increased skeletal VEGF enhances beta-catenin activity and results in excessively ossified bones. The EMBO journal. 2010; 29(2):424—441.      [DOI] 

46.

Frijters R, Fleuren W, Toonen EJM, Tuckermann JP, Reichardt HM, Maaden H, Elsas A, Lierop M, Dokter W, Vlieg J, Alkema W. Prednisolone-induced differential gene expression in mouse liver carrying wild type or a dimerization-defective glucocorticoid receptor. BMC genomics. 2010; 11359.      [DOI] 

45.

Frijters R, Fleuren W, Toonen EJM, Tuckermann JP, Reichardt HM, Maaden H, Elsas A, Lierop M, Dokter W, Vlieg J, Alkema W. Prednisolone-induced differential gene expression in mouse liver carrying wild type or a dimerization-defective glucocorticoid receptor. BMC genomics. 2010; 11359.      [DOI] 

44.

Frijters R, Fleuren W, Toonen EJM, Tuckermann JP, Reichardt HM, Maaden H, Elsas A, Lierop M, Dokter W, Vlieg J, Alkema W. Prednisolone-induced differential gene expression in mouse liver carrying wild type or a dimerization-defective glucocorticoid receptor. BMC genomics. 2010; 11359.      [DOI] 

43.

Wüst S, Tischner D, John M, Tuckermann JP, Menzfeld C, Hanisch U, Brandt J, Lühder F, Reichardt HM. Therapeutic and adverse effects of a non-steroidal glucocorticoid receptor ligand in a mouse model of multiple sclerosis. PloS one. 2009; 4(12):e8202.      [DOI] 

42.

Wüst S, Tischner D, John M, Tuckermann JP, Menzfeld C, Hanisch U, Brandt J, Lühder F, Reichardt HM. Therapeutic and adverse effects of a non-steroidal glucocorticoid receptor ligand in a mouse model of multiple sclerosis. PloS one. 2009; 4(12):e8202.      [DOI] 

41.

Wüst S, Tischner D, John M, Tuckermann JP, Menzfeld C, Hanisch U, Brandt J, Lühder F, Reichardt HM. Therapeutic and adverse effects of a non-steroidal glucocorticoid receptor ligand in a mouse model of multiple sclerosis. PloS one. 2009; 4(12):e8202.      [DOI] 

40.

Hintzen C, Haan C, Tuckermann JP, Heinrich PC, Hermanns HM. Oncostatin M-induced and constitutive activation of the JAK2/STAT5/CIS pathway suppresses CCL1, but not CCL7 and CCL8, chemokine expression. Journal of immunology (Baltimore, Md. : 1950). 2008; 181(10):7341—7349.      [DOI] 

39.

Hintzen C, Haan C, Tuckermann JP, Heinrich PC, Hermanns HM. Oncostatin M-induced and constitutive activation of the JAK2/STAT5/CIS pathway suppresses CCL1, but not CCL7 and CCL8, chemokine expression. Journal of immunology (Baltimore, Md. : 1950). 2008; 181(10):7341—7349.      [DOI] 

38.

Hintzen C, Haan C, Tuckermann JP, Heinrich PC, Hermanns HM. Oncostatin M-induced and constitutive activation of the JAK2/STAT5/CIS pathway suppresses CCL1, but not CCL7 and CCL8, chemokine expression. Journal of immunology (Baltimore, Md. : 1950). 2008; 181(10):7341—7349.      [DOI] 

37.

Wüst S, Brandt J, Tischner D, Kleiman A, Tuckermann JP, Gold R, Lühder F, Reichardt HM. Peripheral T cells are the therapeutic targets of glucocorticoids in experimental autoimmune encephalomyelitis. Journal of immunology (Baltimore, Md. : 1950). 2008; 180(12):8434—8443.      [DOI] 

36.

Wüst S, Brandt J, Tischner D, Kleiman A, Tuckermann JP, Gold R, Lühder F, Reichardt HM. Peripheral T cells are the therapeutic targets of glucocorticoids in experimental autoimmune encephalomyelitis. Journal of immunology (Baltimore, Md. : 1950). 2008; 180(12):8434—8443.      [DOI] 

35.

Wüst S, Brandt J, Tischner D, Kleiman A, Tuckermann JP, Gold R, Lühder F, Reichardt HM. Peripheral T cells are the therapeutic targets of glucocorticoids in experimental autoimmune encephalomyelitis. Journal of immunology (Baltimore, Md. : 1950). 2008; 180(12):8434—8443.      [DOI] 

34.

Kleiman A, Tuckermann JP. Glucocorticoid receptor action in beneficial and side effects of steroid therapy: lessons from conditional knockout mice. Molecular and cellular endocrinology. 2007; 275(1-2):98—108.      [DOI] 

33.

Kleiman A, Tuckermann JP. Glucocorticoid receptor action in beneficial and side effects of steroid therapy: lessons from conditional knockout mice. Molecular and cellular endocrinology. 2007; 275(1-2):98—108.      [DOI] 

32.

Kleiman A, Tuckermann JP. Glucocorticoid receptor action in beneficial and side effects of steroid therapy: lessons from conditional knockout mice. Molecular and cellular endocrinology. 2007; 275(1-2):98—108.      [DOI] 

31.

Textor B, Licht AH, Tuckermann JP, Jessberger R, Razin E, Angel P, Schorpp-Kistner M, Hartenstein B. JunB is required for IgE-mediated degranulation and cytokine release of mast cells. Journal of immunology (Baltimore, Md. : 1950). 2007; 179(10):6873—6880.      [DOI] 

30.

Textor B, Licht AH, Tuckermann JP, Jessberger R, Razin E, Angel P, Schorpp-Kistner M, Hartenstein B. JunB is required for IgE-mediated degranulation and cytokine release of mast cells. Journal of immunology (Baltimore, Md. : 1950). 2007; 179(10):6873—6880.      [DOI] 

29.

Textor B, Licht AH, Tuckermann JP, Jessberger R, Razin E, Angel P, Schorpp-Kistner M, Hartenstein B. JunB is required for IgE-mediated degranulation and cytokine release of mast cells. Journal of immunology (Baltimore, Md. : 1950). 2007; 179(10):6873—6880.      [DOI] 

28.

Tuckermann JP, Kleiman A, Moriggl R, Spanbroek R, Neumann A, Illing A, Clausen BE, Stride B, Förster I, Habenicht AJR, Reichardt HM, Tronche F, Schmid W, Schütz G. Macrophages and neutrophils are the targets for immune suppression by glucocorticoids in contact allergy. The Journal of clinical investigation. 2007; 117(5):1381—1390.      [DOI] 

27.

Tuckermann JP, Kleiman A, Moriggl R, Spanbroek R, Neumann A, Illing A, Clausen BE, Stride B, Förster I, Habenicht AJR, Reichardt HM, Tronche F, Schmid W, Schütz G. Macrophages and neutrophils are the targets for immune suppression by glucocorticoids in contact allergy. The Journal of clinical investigation. 2007; 117(5):1381—1390.      [DOI] 

26.

Tuckermann JP, Kleiman A, Moriggl R, Spanbroek R, Neumann A, Illing A, Clausen BE, Stride B, Förster I, Habenicht AJR, Reichardt HM, Tronche F, Schmid W, Schütz G. Macrophages and neutrophils are the targets for immune suppression by glucocorticoids in contact allergy. The Journal of clinical investigation. 2007; 117(5):1381—1390.      [DOI]